Terms: = Breast cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Treatment
146 results:
1. Uncovering the effect and mechanism of Jiawei Xiaoyao Wan in treating breast cancer complicated with depression based on network pharmacology and experimental analysis.
Bai Y; Niu L; Song L; Dai G; Zhang W; He B; San W; Li S
Phytomedicine; 2024 Jun; 128():155427. PubMed ID: 38513380
[TBL] [Abstract] [Full Text] [Related]
2. Natural compound Byakangelicin suppresses breast tumor growth and motility by regulating SHP-1/jak2/STAT3 signal pathway.
Shi X; Lai Y; Liu W; Zhang X; Cang Y
Biochem Biophys Res Commun; 2024 Apr; 706():149758. PubMed ID: 38484571
[TBL] [Abstract] [Full Text] [Related]
3. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F; Stevens LE; Li Z; Brock JE; Gulvady A; Huang Y; Nakhlis F; Patel A; Force JM; Haddad TC; Ueno N; Stearns V; Wolff AC; Clark AS; Bellon JR; Richardson ET; Balko JM; Krop IE; Winer EP; Lange P; Hwang ES; King TA; Tolaney SM; Thompson A; Gupta GP; Mittendorf EA; Regan MM; Overmoyer B; Polyak K
Breast Cancer Res; 2024 Jan; 26(1):20. PubMed ID: 38297352
[TBL] [Abstract] [Full Text] [Related]
4. Gaillardin inhibits autophagy and induces apoptosis in MCF-7 breast cancer cells by regulating JAK/STAT pathway.
Rajabi S; Tahmasvand Z; Maresca M; Hamzeloo-Moghadam M
Mol Biol Rep; 2024 Jan; 51(1):158. PubMed ID: 38252203
[TBL] [Abstract] [Full Text] [Related]
5. Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Chen P; Long J; Zhang J; Xie F; Wu W; Tian Z; Zhang S; Yu K
Inflamm Res; 2024 Feb; 73(2):263-276. PubMed ID: 38200372
[TBL] [Abstract] [Full Text] [Related]
6. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting jak2/STAT pathway.
Mao F; Gao L; Liu L; Tang Y
J Chemother; 2024 May; 36(3):238-248. PubMed ID: 37916436
[TBL] [Abstract] [Full Text] [Related]
7. Low-Density Lipoprotein Contributes to Endometrial Carcinoma Cell Proliferation, Migration, and Invasion by Activating the JAK-STAT Signaling Pathway.
Shen L; Zhang C; Cui K; Liang X; Zhu G
Anal Cell Pathol (Amst); 2023; 2023():4015167. PubMed ID: 37900720
[TBL] [Abstract] [Full Text] [Related]
8. Mechanisms of Traditional Chinese medicine/natural medicine in HR-positive breast cancer: A comprehensive Literature Review.
Yu Q; Xu C; Song J; Jin Y; Gao X
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117322. PubMed ID: 37866466
[TBL] [Abstract] [Full Text] [Related]
9. Ruyong formula improves thymus function of CUMS-stimulated breast cancer mice.
He B; Guo W; Shi R; Hoffman RD; Luo Q; Hu YJ; Gao J
J Ethnopharmacol; 2024 Jan; 319(Pt 1):117164. PubMed ID: 37717843
[TBL] [Abstract] [Full Text] [Related]
10. DUSP1 regulates the jak2/STAT3 signaling pathway through targeting miR-21 in cervical cancer cells.
Chen H; Ren S; Wan H; Wei W; Luo Y; Cai M
Cell Mol Biol (Noisy-le-grand); 2023 Aug; 69(8):40-44. PubMed ID: 37715430
[TBL] [Abstract] [Full Text] [Related]
11.
Kim H; Song TJ; Yee J; Kim DH; Park J; Gwak HS
Drug Des Devel Ther; 2023; 17():2513-2522. PubMed ID: 37641689
[TBL] [Abstract] [Full Text] [Related]
12. Platinum(IV) Complexes as Inhibitors of STAT3 and Regulators of the Tumor Microenvironment To Control breast cancer.
Cai L; Wang Y; Chen H; Tan Y; Yang T; Zhang S; Guo Z; Wang X
J Med Chem; 2023 Aug; 66(16):11351-11364. PubMed ID: 37578941
[TBL] [Abstract] [Full Text] [Related]
13. Trastuzumab-induced human cardiomyocyte damage through the Notch2/jak2/STAT3 pathway.
Su Z; Liu S; Zou Y; Shan L; Yu M; Xie S; Li X; Jin Y
Clinics (Sao Paulo); 2023; 78():100268. PubMed ID: 37567042
[TBL] [Abstract] [Full Text] [Related]
14. Inonotsutriol E from Inonotus obliquus exhibits promising anti breast cancer activity via regulating the jak2/STAT3 signaling pathway.
Shan P; Wang C; Chen H; Yu J; Zhang H
Bioorg Chem; 2023 Oct; 139():106741. PubMed ID: 37480812
[TBL] [Abstract] [Full Text] [Related]
15. Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase.
Seo J; Park M; Ko D; Kim S; Park JM; Park S; Nam KD; Farrand L; Yang J; Seok C; Jung E; Kim YJ; Kim JY; Seo JH
Cell Mol Life Sci; 2023 Apr; 80(5):132. PubMed ID: 37185776
[TBL] [Abstract] [Full Text] [Related]
16. Jiawei Yanghe Decoction suppresses breast cancer by regulating immune responses via jak2/STAT3 signaling pathway.
You Y; Chen X; Chen X; Li H; Zhou R; Zhou J; Chen M; Peng B; Ji S; Kwan HY; Zou L; Yu J; Liu Y; Wu Y; Zhao X
J Ethnopharmacol; 2023 Nov; 316():116358. PubMed ID: 36933872
[TBL] [Abstract] [Full Text] [Related]
17. Variable Intrinsic Expression of Immunoregulatory Biomarkers in breast cancer Cell Lines, Mammospheres, and Co-Cultures.
Montoyo-Pujol YG; García-Escolano M; Ponce JJ; Delgado-García S; Martín TA; Ballester H; Castellón-Molla E; Martínez-Peinado P; Pascual-García S; Sempere-Ortells JM; Peiró G
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901916
[TBL] [Abstract] [Full Text] [Related]
18. Anemoside A3 Inhibits Macrophage M2-Like Polarization to Prevent Triple-Negative breast cancer Metastasis.
Liu P; Liu Y; Chen L; Fan Z; Luo Y; Cui Y
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838599
[TBL] [Abstract] [Full Text] [Related]
19. Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the jak2/STAT3 signaling pathway.
Ma X; Xu W; Jin X; Mu H; Wang Z; Hua Y; Cai Z; Zhang T
Eur J Pharmacol; 2023 Mar; 942():175529. PubMed ID: 36690054
[TBL] [Abstract] [Full Text] [Related]
20. PDJ amplicon in triple negative breast cancer.
Roesler AS; Malasi S; Koslosky L; Hartmayer P; Naab TJ; Carter JM; Zahrieh D; Hillman D; Leon-Ferre RA; Couch FJ; Goetz MP; Anderson KS; Pockaj BA; Barrett MT
Sci Rep; 2023 Jan; 13(1):618. PubMed ID: 36635351
[TBL] [Abstract] [Full Text] [Related]
[Next]
